A report of six clinical cases of lowered blood cholesterol profile associated with supplementation with polypeptide K (Diabegard®), a polypeptide isolated from the seeds of Momordica charantia Linn by Yong, Yean Sirn et al.
A report of six clinical cases of lowered blood cholesterol profile associated with 
supplementation with polypeptide K (Diabegard®), a polypeptide isolated from the 
seeds of Momordica charantia Linn 
 
Abstract 
Purpose: To assess six patients with Diabegard® supplementation with reference to 
cholesterol profiles. Methods: We report the clinical courses of six individuals taking 
Diabegard® supplementation at 60 and 120 mg/day for 8 weeks. Results: Patients had a 
maximum of 52.13 % reduction in low-density lipoprotein (LDL) cholesterol, 47.67 % 
reduction in triglycerides and 35.78 % reduction in total cholesterol (TC) within 8 weeks of 
Diabegard® supplementation. Interestingly, high-density lipoprotein (HDL) cholesterol 
increased by approximately 23.29 %. Patients also had reduced readings for C-reactive 
protein (CRP) and homocysteine (with maximum reduction of 81.58 % and 57.41 % 
respectively). In some patients, these parameters were elevated prior to supplementation. 
Conclusion: These results suggest that supplementation of Diabegard® will improve patients’ 
cholesterol profile by reduction of LDL and TC. Patients also expressed lower CRP and 
homocysteine indicating reduced inflammation and reduction of cardiovascular diseases 
(CVD) risk. However, patients taking this supplementation are advised to seek medical 
consultation in monitoring their cholesterol and other biochemical profile levels. 
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